The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
COMPARISON OF SCREENING METHODS IN THE DETECTION OF BLADDER CANCER
Abstract
PURPOSE: We prospectively evaluate and compare the sensitivity and specificity of urine cytology, BTA stat, NMP22, fibrin/fibrinogen degradation products (FDP), telomerase, chemiluminescent hemoglobin and hemoglobin dipstick to detect bladder cancer. MATERIALS AND METHODS: Single voided specimens were obtained from 57 patients with bladder cancer, and 139 without evidence of bladder malignancy on cystoscopy or a negative biopsy of indeterminate lesions. A cytology report was available for 125 patients and interpreted independently. BTA stat, NMP22 and FDP were analyzed according to manufacturer specifications. The telomerase assay was performed on cells collected from urine by centrifugation in preparation for polymerase chain reaction based amplification using the telomeric repeat amplification protocol assay. The chemiluminescent screening assay for hemoglobin in urine uses the pseudoperoxidase activity of hemoglobin on hydrogen peroxide and subsequent oxidation of 7-dimethylaminonaphthalene-1,2-dicarbonic acid hydrazide to generate chemiluminescence emission. Hemoglobin dipstick was interpreted as positive if the hemoglobin content in the urine was trace or greater. RESULTS: Overall sensitivity with urine cytology, BTA stat, NMP22, FDP, telomerase, chemiluminescent hemoglobin and the hemoglobin dipstick was 44, 74, 53, 52, 70, 67 and 47%, respectively. Specificity with cytology, telomerase and FDP was high (95, 99 and 91%, respectively) but BTA stat, NMP22 (optimized), chemiluminescent hemoglobin (optimized) and the hemoglobin dipstick demonstrated lower specificity of 73, 60, 63 and 84%, respectively. Stepwise logistic regression analysis revealed that for all tumors, and within each tumor grade and stage telomerase had the strongest association with bladder cancer among all tests (69% overall concordance). Telomerase was also positive in 91% of the patients (10 of 11) with carcinoma in situ. CONCLUSIONS: Urinary telomerase had the highest combination of sensitivity and specificity (70 and 99%, respectively) for bladder cancer screening in these patients. It was the strongest predictor with superior accuracy in patients with grade 1 and noninvasive tumors (pTa), and extremely useful in patients with carcinoma in situ. Telomerase appears to be promising and outperformed cytology, BTA stat, NMP22, FDP, chemiluminescent hemoglobin and hemoglobin dipstick in the prediction of bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.6 · Cited by 2,341
Diagnostic Cytology and Its Histopathologic Bases.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-6-1341_1 · Cited by 775
Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., & Senger, D. R. (1993) · PubMed · Cited by 564
Nucleic Acid-Based Methods for the Detection of Cancer
Sidransky, D. (1997) · Science · doi:10.1126/science.278.5340.1054 · Cited by 405
Nagy, J. A., Brown, L. F., Senger, D. R., Lanir, N., Van De Water, L., Dvorak, A. M., & Dvorak, H. F. (1989) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(89)90004-8 · Cited by 380
Telomeres, Telomerase, and Immortality
Rhyu, M. S. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.12.884 · Cited by 380
Different angiogenic pathways characterize superficial and invasive bladder cancer.
O’Brien, T., Cranston, D., Fuggle, S., Bicknell, R., & Harris, A. L. (1995) · PubMed · Cited by 291
Yoshida, K., Sugino, T., Tahara, H., Woodman, A., Bolodeoku, J., Nargund, V., Fellows, G., Goodison, S., Tahara, E., & Tarin, D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970115)79:2<362::aid-cncr20>3.0.co;2-y · Cited by 193
Detection of Telomerase Activity in Exfoliated Cells in Urine From Patients With Bladder Cancer
Kinoshita, H., Ogawa, O., Kakehi, Y., Mishina, M., Itoh, N., Yamada, H., Terachi, T., & Yoshida, O. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.10.724 · Cited by 141
Telomerase activity in human bladder cancer.
Lin, Y., Miyamoto, H., Fujinami, K., Uemura, H., Hosaka, M., Iwasaki, Y., & Kubota, Y. (1996) · PubMed · Cited by 121
Chen, K., Chan, S. H. H., Chang, L. S.-S., & Chan, J. Y. H. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00078 · Cited by 113
Applications of telomerase in urologic oncology
Landman, J., Kavaler, E., Droller, M. J., & Liu, B. C. ‐. (1997) · World Journal of Urology · doi:10.1007/bf02201983 · Cited by 17
Cited by
Systematic Reviews of Diagnostic Test Accuracy
Leeflang, M. M. G., Deeks, J. J., Gatsonis, C., & Bossuyt, P. M. M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-12-200812160-00008 · Cited by 1,124
Urine Markers for Bladder Cancer Surveillance: A Systematic Review
van Rhijn, B. W. G., van der Poel, H. G., & van der Kwast, T. H. (2005) · European Urology · doi:10.1016/j.eururo.2005.03.014 · Cited by 530
Lotan, Y., & Roehrborn, C. G. (2003) · Urology · doi:10.1016/s0090-4295(02)02136-2 · Cited by 474
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
Lokeshwar, V. B., Habuchi, T., Grossman, H. B., Murphy, W. M., Hautmann, S. H., Hemstreet, G. P., Bono, A. V., Getzenberg, R. H., Goebell, P., Schmitz-Dräger, B. J., et al. (2005) · Urology · doi:10.1016/j.urology.2005.08.064 · Cited by 431
Mowatt, G., Zhu, S., Kilonzo, M., Boachie, C., Fraser, C., Griffiths, T., N'Dow, J., Nabi, G., Cook, J., & Vale, L. (2010) · Health Technology Assessment · doi:10.3310/hta14040 · Cited by 313
Metadata
- Authors
- RAMAKUMAR, S., BHUIYAN, J., BESSE, J. A., ROBERTS, S. G., WOLLAN, P. C., BLUTE, M. L., & O'KANE, D. J.
- Venue
- Journal of Urology
- Published
- 1999-02
- Volume
- 161
- Issue
- 2
- Pages
- 388-394
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2167120646
- Cited by
- 335
- References
- 14
- FWCI
- 36.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.